Nutrient Deficiencies and GLP-1 Therapies: A Comprehensive Guide

The rising use of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, for weight management and type 2 diabetes is transforming healthcare. While these medications offer significant benefits, a growing body of evidence highlights the potential for nutrient deficiencies. This article explores the mechanisms behind these deficiencies, identifies at-risk individuals, and provides practical guidance for healthcare professionals and patients to mitigate these risks.

How GLP-1 Therapies Impact Nutrient Absorption

GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists work by promoting satiety, reducing appetite, and decreasing energy intake. [1] This therapeutic effect, while desirable for weight loss, can inadvertently lead to reduced food consumption and, decreased absorption of essential nutrients. If dietary choices don’t actively shift towards nutrient-dense foods, intake of protein, vitamins, and minerals will inevitably decline. Gastrointestinal side effects, such as nausea, vomiting, diarrhea, and constipation – particularly during dose escalation – can further exacerbate these deficiencies. [2]

Evidence of Nutrient Deficiencies

Retrospective analyses reveal a concerning trend: nutrient deficiencies are increasingly documented in patients initiating GLP-1RA therapy. One large study showed that 12.7% of patients were diagnosed with a nutrient deficiency after 6 months, rising to 22.4% after 12 months. [2] Vitamin D deficiency is the most commonly reported, but deficiencies in other key nutrients are also observed.

Food protocol examinations demonstrate that GLP-1RA users often have intakes below reference values for fiber, calcium, iron, magnesium, potassium, choline, and vitamins A, C, D, and E. While protein intake may appear adequate as a percentage of total calories, the absolute amount (grams per day or per kilogram of body weight) is often insufficient, especially with significant calorie restriction.

Prioritizing Protein and Bone Health

Weight loss, even with GLP-1 therapies, inevitably involves some loss of fat-free mass. This is particularly concerning in older adults, individuals with low activity levels, or those experiencing rapid weight loss. Prioritizing protein intake is crucial. The German Nutrition Society (DGE) recommends 0.8 g/kg/day for adults aged 19-65, and 1.0 g/kg/day for those 65 and older. Calculations should be based on ideal body weight for overweight individuals. [2]

Maintaining bone health is equally important, as bone mineral density can decrease with substantial weight loss, especially in postmenopausal women and those with pre-existing calcium and vitamin D deficiencies. Combining GLP-1RA therapy with structured exercise appears to be the most effective strategy for preserving bone health. [2] Adequate calcium and vitamin D intake are also essential; the DGE recommends 20 µg/day (800 IU) of vitamin D.

Addressing Hair Loss and Micronutrient Status

Hair loss is a frequently reported side effect of rapid weight loss and is increasingly associated with GLP-1 therapy. It may be linked to telogen effluvium, triggered by weight loss as a stressor, reduced energy and protein intake, and potential micronutrient deficiencies (iron, zinc, vitamin D). [2] While a direct causal link to the medication hasn’t been definitively established, nutritional countermeasures are warranted.

Practical Guidance for Healthcare Professionals

A proactive approach to monitoring and managing potential nutrient deficiencies is essential. This includes:

• Brief Screening: Assess eating patterns, protein sources, fruit and vegetable consumption, dairy intake, vegetarian/vegan diets, alcohol consumption, portion sizes, and gastrointestinal symptoms.
• Risk Group Identification: Focus on older adults, frail individuals, those experiencing rapid weight loss, patients with persistent nausea or vomiting, individuals with known deficiencies, or those following restrictive diets.
• Targeted Monitoring: Consider laboratory testing (complete blood count, ferritin, transferrin saturation, 25-OH vitamin D, vitamin B12, folate, magnesium) in high-risk patients.
• Nutritional Counseling: Emphasize nutrient-dense food choices, increased protein intake per portion, and strategies to manage gastrointestinal side effects.

The “Overfed but Undernourished” Phenomenon

It’s important to recognize that many individuals with obesity are “overfed but undernourished” – consuming excess calories but lacking essential micronutrients. [2] GLP-1 therapies don’t *cause* these deficiencies, but they can produce them more apparent by reducing overall food intake. This presents an opportunity for healthcare providers to address underlying nutritional imbalances.

Pharmacists can play a vital role by providing guidance on protein intake, fiber-rich foods, calcium sources, iron-conscious diets, and strategies to prevent constipation. The focus should be on improving nutrient quality, not simply reducing quantity.

Looking Ahead

As GLP-1-based therapies develop into increasingly prevalent, a comprehensive understanding of their impact on nutritional status is paramount. Ongoing research and proactive monitoring will be crucial to ensure the safe and effective use of these medications and to optimize patient outcomes. [3]